Key result
Hospital site linked to ~70% variation in inpatient mortality for COVID-19 with myocardial injury.
Why the study?
Guidelines on best practices for patients with COVID-19 and elevated cardiac troponin remain uncertain, and site-level variability in care and outcomes is not well characterized.
Observational (n=6,234)
Yes
During the early COVID-19 pandemic, there was significant institutional variability in the care and outcomes of patients with COVID-19 and myocardial injury, with very low but increasing use of invasive coronary angiography over time.
Answers are grounded in this paper and cite their sources.
Moderate site variability signals potential care disparities; leaves open whether standardization improves outcomes in COVID-19 myocardial injury.
Background: Elevated cardiac troponin (cTn) levels in patients with COVID-19 has been associated with worse outcomes. Guidelines on best practices of those patients remain uncertain. Methods: We included patients with COVID-19 and cTn above the assay-specific upper limit of normal (ULN) enrolled in the American Heart Association's COVID-19 registry between March 2020-January 2021. Site-level variability in invasive coronary angiography, LVEF assessment, ICU utilization, and inpatient mortality were determined by calculating adjusted median odds ratio (MOR) using hierarchical logistic regression models. Temporal trends were assessed with Cochran-Armitage trend test. Results: Among 32,636 patients, we included 6234 (19.4 %) with cTn above ULN (age 68.7 ± 16.0 years, 56.5 % male, 51.5 % Caucasian), of whom 1365 (21.6 %) had ≥5-fold elevations. Across 55 sites, the median rate of invasive coronary angiography was 0.1 % with adjusted MOR 1.5(1.0,2.3), median LVEF assessment was 25.5 %, MOR 3.0(2.2,3.9), ICU utilization was 41.7 %, MOR 2.2(1.8,2.6), and mortality was 20.9 %, MOR 1.7(1.5,2.0). Over time, we noted a significant increase in invasive coronary angiography (p-trend = 0.001), and LVEF assessment (p-trend<0.001), and reduction in mortality (p-trend<0.001), without significant change in ICU admissions (p-trend = 0.08). Similar variability and temporal trends were seen among patients with ≥5-fold cTn elevation. Conclusions: The use of invasive coronary angiography among patients with COVID-19 and myocardial injury was very low during the early pandemic. We found moderate institutional variability in processes of care with an uptrend in invasive catheterization and LVEF assessment, and downtrend in mortality. Comparative effectiveness studies are needed to examine whether variability in care is associated with differences in outcomes.
No takes yet. Share an insight, caveat, or question.
Sammour et al. (2023) conducted an observational in COVID-19 and myocardial injury (n=6,234). Hospital site (institutional care) vs. Across 55 sites was evaluated on Inpatient mortality (site-level variability) (MOR 1.7, 95% CI 1.5-2.0). Across 55 sites, there was moderate institutional variability in inpatient mortality among patients with COVID-19 and myocardial injury.
Synapse has enriched 10 related papers. Consider them for comparative context: